肿瘤免疫检查点靶向治疗的研究进展

The progress in tumor immune checkpoint-targeted immunotherapy

靶向免疫检查点的治疗是众多抗肿瘤免疫的有效策略之一,在抗肿瘤免疫治疗中诱发持续的肿瘤缓解。抗CTLA-4单抗,抗PD-1单抗以及抗PD-L1单抗的安全性及临床疗效研究为肿瘤治疗带来了新突破,针对免疫检查点的靶向治疗已成为肿瘤治疗的新方向。本文对近年来与肿瘤免疫靶向治疗的研究进展进行综述。

Cancer therapy targeting immune checkpoints such as programmed cell death protein 1（PD-1）,programmed cell death 1 ligand 1（PD-L-1）and cytotoxic T lymphocyte antigen 4（CTLA-4）has achieved noteworthy benefit in multiple cancers by blocking immune-inhibitory signals and enabling patients to produce an effective antitumor immune response.The Cancer therapy of the monoclonal antibodies against CTLA-4,PD-1 and PD-L-1 has brought a promising future for cancer treatment.In this review,we mainly discuss the progress in the tumor immune checkpoint-targeted immunotherapy in recent years.